Kyverna Therapeutics (KYTX) Stock Price, News & Analysis

Company Overview

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions. Kyverna’s approach centers on scalable manufacturing processes and precision cell engineering, enabling the production of off‐the‐shelf therapeutic products with defined dosing and predictable pharmacology. Collaborations with academic institutions and biotech partners support its pipeline advancement and translational research efforts.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Kyverna Therapeutics draws on a leadership team with deep expertise in cell therapy, immunology and bioprocess development. The company operates research and manufacturing facilities in the Greater Boston area and engages with regulatory authorities in North America and Europe to advance its clinical programs. Kyverna’s strategic vision is to pioneer durable, disease‐modifying treatments that address high‐unmet needs in autoimmune and inflammatory disorders.

Key Stats

• Today's Range: $5.91 to $6.18
• 50-Day Range: $3.02 to $6.52
• 52-Week Range: $1.78 to $7.20
• Volume: 134,286 shs
• Average Volume: 374,648 shs
• Market Capitalization: $260.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.60
• Consensus Rating: Buy

Kyverna Therapeutics Stock Analysis - MarketRank™

Kyverna Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 733rd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Buy

Consensus Rating

Kyverna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Kyverna Therapeutics has a consensus price target of $16.60, representing about 175.7% upside from its current price of $6.02.

Amount of Analyst Coverage

Kyverna Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.29) to ($3.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kyverna Therapeutics is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kyverna Therapeutics is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kyverna Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.55% of the float of Kyverna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kyverna Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kyverna Therapeutics has recently increased by 19.26%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kyverna Therapeutics does not currently pay a dividend.

Dividend Growth

Kyverna Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.55% of the float of Kyverna Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Kyverna Therapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kyverna Therapeutics has recently increased by 19.26%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Kyverna Therapeutics this week, compared to 6 articles on an average week.

Search Interest

13 people have searched for KYTX on MarketBeat in the last 30 days. This is an increase of 1,200% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.00% of the stock of Kyverna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 18.08% of the stock of Kyverna Therapeutics is held by institutions.

KYTX Stock Analysis - Frequently Asked Questions

How have KYTX shares performed this year?

Kyverna Therapeutics' stock was trading at $3.74 on January 1st, 2025. Since then, KYTX stock has increased by 61.0% and is now trading at $6.02.

How were Kyverna Therapeutics' earnings last quarter?

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) announced its earnings results on Tuesday, August, 12th. The company reported ($0.97) EPS for the quarter, topping analysts' consensus estimates of ($1.00) by $0.03.

When did Kyverna Therapeutics IPO?

Kyverna Therapeutics (KYTX) raised $319 million in an IPO on Thursday, February 8th 2024. The company issued 14,500,000 shares at a price of $22.00 per share.

How do I buy shares of Kyverna Therapeutics?

Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kyverna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/02/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KYTX
• Previous Symbol: NASDAQ:KYTX
• CIK: 1994702
• Web: kyvernatx.com
• Phone: 510-626-8331
• Fax: N/A
• Employees: 96
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Kyverna Therapeutics: $16.60
• High Price Target: $24.00
• Low Price Target: $10.00
• Potential Upside/Downside: +178.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.48 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -64.98%
• Return on Assets: -56.17%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.39
• Quick Ratio: 5.39

Sales & Book Value

• Annual Sales: $7.03 million
• Price / Sales: 36.73
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.17 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 43,250,000
• Free Float: 33,732,000
• Market Cap: $258.20 million
• Optionable: Optionable
• Beta: 3.69